about
Cost containment of pharmaceutical use in Iceland: the impact of liberalization and user charges.SearCh for humourIstic and Extravagant acroNyms and Thoroughly Inappropriate names For Important Clinical trials (SCIENTIFIC): qualitative and quantitative systematic study.Psychometric properties of the Icelandic NEO-FFI in a general population sample compared to a sample recruited for a study on the genetics of addiction.The Nordic countries as a cohort for pharmacoepidemiological research.Future methods in pharmacy practice research.Primary non-adherence to prescribed medication in general practice: lack of influence of moderate increases in patient copayment.No struggle, no strength: how pharmacists lost their monopoly.Characteristics and drug utilization patterns for heavy users of prescription drugs among the elderly: a Danish register-based drug utilization study.Do patients initiate therapy? Primary non-adherence to statins and antidepressants in Iceland.Social Pharmacy and Clinical Pharmacy-Joining Forces.Introducing Pharmaceutical Care to Primary Care in Iceland-An Action Research Study.Factors influencing the detection rate of drug-related problems in community pharmacy.The lay user perspective on the quality of pharmaceuticals, drug therapy and pharmacy services--results of focus group discussions.Psychotropic drug use among Icelandic children: a nationwide population-based study.Opportunities and challenges in social pharmacy and pharmacy practice research.[Providing emergency contraceptive pills in pharmacies].A population-based study of stimulant drug treatment of ADHD and academic progress in children.The association between lifting an administrative restriction on antidepressant dispensing and treatment patterns in Iceland.Cost-containment as part of pharmaceutical policy.Multifaceted Pharmacist-led Interventions in the Hospital Setting: A Systematic Review.Mandatory medication content in the curricula of six healthcare personnel types with patient contact in DenmarkGeneral practitioners' continuation and acceptance of medication changes at sectorial transitions of geriatric patients - a qualitative interview studyStudying and evaluating pharmaceutical policy—becoming a part of the policy and consultative processPharmaceutical Policy and the Pharmacy Profession*Pharmaceutical Policy and the Lay Public*The argument for pharmaceutical policyInterviewing the Moderator: An Ancillary Method to Focus GroupsUnavailable prescriptions at Danish community pharmacies: A descriptive studyFrequency of undocumented medication discrepancies in discharge letters after hospitalization of older patients: a clinical record review study.[The use of herbal medicines, food supplements, and OTCs - design and testing of a questionnaire.].[Quality indicators of drug therapy at hospital admission among elderly patients][Pharmaceutical Care at the primary care clinic in Garðabær - number and type of drug therapy problems identified among elderly clients]Identifying and assessing potential harm of medication errors and potentially unsafe medication practices in paediatric hospital settings: a field studyPatients', Pharmacy Staff Members', and Pharmacy Researchers' Perceptions of Central Elements in Prescription Encounters at the Pharmacy Counter
P50
Q34007237-D8B1F9A8-1624-4F4A-8203-39A4EA908978Q34710448-2C0A9B71-072C-409F-8C0A-F8976F571884Q37453665-49D1834A-9B70-4A1E-9116-E53BE046D346Q37644540-FBCA52E7-34B9-4D69-9DFB-A748835CAC7BQ38864199-5A17E61B-9DAF-4832-A95E-83F3EBECB50FQ39242175-9F9595E1-2A49-4D4A-B99C-80218F307D56Q39500482-B17CB646-7328-43E1-8A20-B331D0D0732BQ41014016-22723CDB-BD18-4B85-8BEE-15E8485ED878Q41484191-68F5E47A-F2F5-479D-8015-002F706C136BQ41787666-CA5A92AD-B6C6-4B01-9612-36FCD642A80CQ42131274-596E86B6-B144-4258-94D0-80F37EB58D4AQ42618184-7557856A-E479-4C90-8FA5-65066F505257Q42687732-0B8130B0-CFAA-4BF5-9FCA-DD4B456E36A7Q43815478-8D0F378C-D2E9-41ED-90EC-E15C30C9C3D2Q44209716-BF681FC5-928A-43CC-92CC-B4CDF041E1F6Q46023197-BDA5026C-DDED-4700-9051-58C77A0D4613Q47579263-87745AE7-CB86-4479-B6F2-671681EED860Q48491187-5FDB4EAF-ED2C-4DBB-A610-4A0239E8750DQ48708436-68B0062C-BA74-4952-B85C-9EC8F684BCBFQ53283365-92970C0C-4A29-4A96-AE57-A2B425725A88Q57470204-290A46E8-2A20-4392-AEC0-A0A4DA177AEBQ57470292-59F4B36D-0E7A-4EB9-97E6-209812B02659Q57660155-D0D5AD9D-B9E5-4DE1-BFFD-BCF85D9AB319Q57660162-60BF7827-6021-4F06-8C09-FC98ADB7E28DQ57660171-7E7596F1-3343-4525-8556-49C7C81C0C10Q57660182-0C934CCC-D585-4067-B2FE-2B39BE1DD5BCQ57660190-061D1DE8-A13E-4B5F-AFC5-4A7F8EB879DAQ64110864-36160EF8-19AA-4C31-A4A2-A3C8E7D599D0Q64886151-F30D569D-B3E2-4CB1-B5B2-D43FAE5E615AQ80185420-CB2E174D-5D9D-4592-9404-2FA08C9BC7C9Q82447723-3BB4953F-6F2F-485B-B0FF-A3D963360989Q89768431-ECC90261-A70D-4613-872F-9618A1314447Q91290387-243E60E5-06E1-4A90-AF87-2569BF9C4067Q91657742-5FD938EF-6C59-4245-85F2-6E07E55A7480
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5354-2976
@en
name
Anna Birna Almarsdottir
@ast
Anna Birna Almarsdottir
@en
Anna Birna Almarsdottir
@es
Anna Birna Almarsdottir
@nl
type
label
Anna Birna Almarsdottir
@ast
Anna Birna Almarsdottir
@en
Anna Birna Almarsdottir
@es
Anna Birna Almarsdottir
@nl
prefLabel
Anna Birna Almarsdottir
@ast
Anna Birna Almarsdottir
@en
Anna Birna Almarsdottir
@es
Anna Birna Almarsdottir
@nl
P106
P1153
6701329670
P21
P214
109152138579710980246
P31
P496
0000-0002-5354-2976